Swiss Medica Inc., Innovative Products That Improve Peoples' Lives

8/11/2004 10:58:28 AM ET

SWISS MEDICA ANNOUNCES THOMAS QUINN AS VICE-PRESIDENT, U.S. OPERATIONS

Stock Symbol: OTC BB: SWME

August 11, 2004

SWISS MEDICA ANNOUNCES THOMAS QUINN AS VICE-PRESIDENT, U.S. OPERATIONS

Toronto, Canada – Grant Johnson, President of Swiss Medica, is pleased to announce Tom Quinn as the

Company’s new Vice President, U.S. Operations.

Previously, Mr. Quinn held executive management roles with Warner-Lambert Consumer Healthcare (NYSE:

WLA), CIGNA Health Care (NYSE: CI), and TravelCLICK. Before that, he held positions in sales and marketing,

in the U.S. and Europe, during a sixteen-year career at Procter & Gamble (NYSE: PG). His sales expertise

includes a proven track record in both consumer goods and healthcare. Mr. Quinn’s successes encompass

sales leadership, business development, product launches and turnarounds and general management.

Tom Quinn said, “Our mission, beginning with the O24 launch, is to create a highly effective retailer distribution

and consumer sell-through capability for Swiss Medica brands. This will ensure that O24 quickly reaches its full

potential and will be the model Swiss Medica will use to successfully launch and attract additional products in the

future.”

Among Mr. Quinn’s stellar achievements was leading the Warner-Lambert/Glaxo joint venture Zantac 75 OTC

switch. That launch was acclaimed “Best of the Year” by the NWDA (Natural Wholesale Drug Assoc.). His sales

force was voted “Most Effective in Industry” by NWDA and “Best in Class” for category management by

Supermarket Business. For the first time, Warner-Lambert was chosen “Vendor of the Year” by both Wal-Mart

(NYSE: WMT) and Target (NYSE: TGT).

Grant Johnson said, “We are delighted to have an experienced, proven and highly successful sales and

marketing executive in Tom Quinn leading the O24 pain relief product launch into the United States marketplace,

and establishing Swiss Medica as an emerging brand name in its category. His track record at Fortune 500

companies and smaller firms should provide Swiss Medica with the necessary element for a successful U.S. roll

out of our flagship product.”

About Swiss Medica Inc.

Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our

market share through focused distribution strategies in multiple sales channels. Swiss Medica’s mission is to be

a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please

visit our websites at www.swissmedica.com and

Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the

United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking

statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close

transactions being contemplated, risks related to international sales and potential foreign currency exchange

fluctuations, continued acceptance of Swiss Medica’s products, increased levels of competition, technological

changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica’s

periodic reports filed with the United States Securities and Exchange Commission and other regulatory

authorities.

Investor Relations Contact:

David Jones

Swiss Medica Inc.

1 866 485 4243